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Pharmacogenomic Promises: 
Refl ections on Semantics, 
Genohype, and Global Justice
Bryn Williams-Jones and Vural Ozdemir
Pharmacogenomics is an emerging medical specialty that investigates 
the role of genetic factors in drug response and adverse effects. It differs 
from its predecessor discipline pharmacogenetics by having a larger scope 
of inquiry: pharmacogenomics aims to characterize genetic differences 
among patients across the entire human genome. By contrast, pharmaco-
genetic studies typically involve investigations of single or a limited set of 
genes (Ozdemir and Lerer 2005). It is anticipated that a better understand-
ing of genetic factors underlying individual differences in drug effects will 
help the customization of drug prescriptions.
 The fi eld of pharmacogenomics had its origins in 1950s with the cre-
ation of human biochemical genetics and the discovery of single gene 
variations associated with enzyme defi ciencies. These enzyme defects 
were responsible for certain unexpected adverse drug reactions, such as 
peripheral neuropathy in slow-acetylators of the anti-tuberculosis drug 
isoniazid. Twin studies in the 1970s subsequently confi rmed the important 
role of genetics in drug disposition. These developments did not, however, 
permeate through mainstream medical research until the late 1990s, when 
DNA technologies spun off from the Human Genome Project became more 
widely available in clinical and research laboratories. 
 A key element of pharmacogenomic research is that it deals with ques-
tions of variability in drug effects. This approach runs counter to certain 
established and deterministic norms in medical practice and pharma-
ceutical industry drug development (Olivier et al. 2008). That is, drug 
researchers, policy makers, and industry representatives have traditionally 
approached drug effi cacy and safety at a population level; rather little 
attention has been given to subpopulations or persons with a differential 
risk for treatment resistance or drug toxicity.
 Much of the technical debate on pharmacogenomics and the promise 
of personalized medicine has centred on upstream applications that can 
facilitate research to discover new drug targets or the identifi cation of 
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patients with different molecular subtypes of disease. Although person-
alization of the choice of medicines or their doses is often highlighted 
in forward-looking statements on pharmacogenomics, little is mentioned 
about exactly how this may be achieved. Pharmacogenomics has also been 
advocated as a means of improving the effi ciency (and thus reducing the 
cost) of drug discovery, clinical trials, and the drug approval process. But 
the very nature of the pharmacogenomics approach — its emphasis on 
individual variability in treatment outcomes — threatens the traditional 
business model associated with one-size-fi ts-all drug development and 
commercialization. To this end, refl ections on the ethical and policy con-
cerns associated with pharmacogenomic research have tended to focus on, 
for example, informed consent and banking of genetic material in clinical 
trials, privacy considerations, or potential for stigmatization (Tutton and 
Corrigan 2004; Weijer and Miller 2004).
 As pharmacogenomic applications emerging from industry and academic 
laboratories start to enter the doctor’s offi ce (e.g., as genetic tests and indi-
vidualized drug therapies), numerous other ethical concerns arise. In this 
chapter, we analyze three of these: (1) the semantic representations and 
signifi cance of genetics language in public and policy discourse on drug 
effi cacy and safety, (2) the implications of excessive genohype for the realis-
tic application of pharmacogenomic technologies, and (3) the promise and 
challenges of applying pharmacogenomics for essential medicines used to 
treat diseases predominantly affecting people in developing countries. 
Historical Context and Genealogy of Personalized Therapeutics
During the last century, and in particular the last thirty years, contem-
porary Western medicine has shifted its focus from the development of 
pharmaceutical drugs (whether prescription or over-the-counter) for rare 
medical conditions and infectious diseases to the development of treat-
ments for common illnesses. Drugs are being used to alleviate both acute 
and chronic conditions, and as prophylactic measures to reduce risk of 
long-term morbidity and mortality — in the West, drugs now constitute the 
primary treatment modality. Although drugs can be life-saving in some 
patients, there is growing concern over the marked uncertainty in drug 
toxicity or effi cacy; these concerns relate both to new compounds in clin-
ical trials and those already in clinical use. 
 A review of the published data on the effi cacy of major drug classes being 
prescribed for common human diseases concluded that response rates vary 
substantially across various therapeutic areas. For example, while 80 per-
cent of patients responded positively to pain medications such as COX-2 
inhibitors, response rates dropped to 30 percent for treatments directed at 
Alzheimer’s disease and 25 percent for cancer chemotherapies (Table 11.1). 
Although many drugs in the major therapeutic classes can be life-saving, 
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only about 50 percent of patients actually respond positively to their medica-
tions (Spear, Heath-Chiozzi, and Huff 2001). Of serious concern, then, are 
the remaining 50 percent of patients for whom their medication is either 
ineffective or even toxic. 
 A meta-analysis of prospective studies investigating drug safety in the 
United States indicated that 6.7 percent of hospitalized patients experience 
serious adverse drug reactions (ADRs), while 0.3 percent die from toxic 
drug effects. This translates into more than two million serious ADRs and 
an annual death rate of 106,000 patients. These estimates rank ADRs as the 
fourth leading cause of death in the United States (Lazarou, Pomeranz, and 
Corey 1998a). Subsequent extended analyses of thirty-two non-US stud-
ies from industrialized countries support the conclusion that fatal ADRs 
are a signifi cant global public health concern (Lazarou, Pomeranz, and 
Corey 1998b). Interestingly, serious ADRs were observed during treatments 
with usual drug dosages, despite the exclusion of cases that were due to 
intentional or accidental overdose, human errors in drug administration, 
non-compliance, or drug abuse.
 The patient and public health implications of non-response or toxic reac-
tion to common medications, and the development of means to reduce 
these negative effects, have for decades been core research questions in the 
medical sciences (Reidenberg 2003). By better understanding the degree of 
Table 11.1
Response rates of patients to major drug 
classes in selected therapeutic areas
Therapeutic area Effi cacy rate (%)
Alzheimer’s 30
Analgesics (COX-2) 80
Asthma 60
Cardiac arrhythmias 60
Depression (SSRI) 62
Diabetes 57
HIV 47
Incontinence 40
Migraine (acute) 52
Migraine (prophylaxis) 50
Oncology 25
Osteoporosis 48
Rheumatoid arthritis 50
Schizophrenia 60
Source: Reproduced with permission from Spear, Heath-
Chiozzi, and Huff (2001).
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and mechanisms governing the predictability of drug effects, biomedical 
scientists — and especially clinical pharmacologists — aim to rationalize the 
choice of drugs and customize dosages for individual patients and sub-
populations, that is, the goal is personalized medicines (Sheiner 1997).
 Some experts suggest that the origins of personalized medicines can be 
dated to about 510 BCE when Pythagoras, in Croton, in southern Italy, 
warned of “dangers of some, but not other, individuals who eat the fava 
bean” (discussed in Nebert 1999). The molecular basis of this historical 
observation was later found to be haemolytic anaemia attributable to 
glucose-6-phosphate dehydrogenase defi ciency (Nebert 1999). Interest in 
the rational choice of therapies can be traced to the eighteenth century, 
when English naval surgeon James Lind demonstrated in 1747, in the fi rst 
formal comparative trial of its kind, that scurvy could be cured by citrus 
juice but not by the other leading remedies of the day — cider, vinegar, sea 
water, or purgative mixtures (Sutton 2004).
 Numerous recent policy initiatives have added support to the drive to 
develop personalized therapies (Kohn, Corrigan, and Donaldson 2000). 
Pharmaco-epidemiology studies have, however, highlighted important 
barriers to the rationalization of therapeutics, due in large part to the lack 
of reliable predictors for the marked inter-individual and population-to-
population variability in drug treatment outcomes (Spear, Heath-Chiozzi, 
and Huff 2001).
 One of the prominent research strategies for discovering and applying 
the requisite genetic predictors (i.e., biomarkers) needed to develop per-
sonalised medicines is pharmacogenomics. Employing a broad survey of 
the human genome made possible by recent advances in DNA sequencing 
and the identifi cation of thousands of single nucleotide polymorphisms, 
pharmacogenomics studies the role of genetics on inter-individual and 
population-to-population variability in drug effects (Evans and McLeod 
2003). As single nucleotide polymorphisms, genes or other biological mark-
ers are identifi ed and associated with particular drug effects (therapeutic 
response, toxicity, or treatment-resistance), it becomes possible to offer 
genetic testing to patients or population groups in order to individualize 
the selection of the type and/or dosage of a medication, thereby improving 
effi cacy and reducing the risk of ADRs.
 An important difference, then, between the present interest in phar-
macogenomic-guided personalized medicine and previous attempts using 
more descriptive or demographic predictors (e.g., age, ethnicity, geo-
graphic origins) is that suffi cient causal information now exists to allow 
for the development of DNA-based diagnostics and customized therapeutic 
interventions. This has led to the development of drugs such as Abacavir 
(for HIV/AIDS), Herceptin (for metastatic breast cancer) and Gleevec (for 
chronic myeloid leukemia). The hope is that such fi rst generation pharma-
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cogenomic applications will revolutionize medical practice by inaugurat-
ing the age of personalized medicines.
 However, despite growing knowledge of the importance of genetics in 
drug effects, there is also an awareness that environmental and social 
factors play a signifi cant role. Factors such as poor nutrition, low socio-
economic status, lack of education, or inadequate health insurance con-
tribute substantially to lack of effi cacy or toxicity, a situation that applies 
to both mainstream and pharmacogenomic drugs (Corrigan 2002). Such a 
complex interaction of genetic, social, and environmental factors therefore 
requires more detailed and nuanced social and epidemiological research 
to better understand the etiology of drug affects. Consequently, although 
research into personalized medicine has become fi rmly placed on the 
social policy and science agendas and is a topic of public and media inter-
est, this interest has been matched by increased scrutiny of the promises, 
timelines, and likely impact of pharmacogenomics on therapeutics and 
patient care (Corrigan 2005; Ozdemir and Lerer 2005).
Semantics Revisited: “Genetics” in “Biological Dogma” 
and “Risk Assessment” 
The elucidation of the structure and functioning of DNA, and the growing 
understanding and application of genetic information in the biological 
sciences, has led to the deployment of powerful metaphorical language in 
scientifi c, public, and policy discussions. The human genome, for example, 
has variously been described as a “blueprint,” an “instruction book,” or, 
in the words of former US president Bill Clinton, “the language in which 
God created life.” In drawing the map of the human genome, scientists 
are said to be building an “encyclopaedia,” an orderly reference book that 
can be deciphered to predict health and well-being, individual behaviour, 
and personal destiny. Personalized medicines, gene therapies, genetically 
modifi ed organisms, and genetic tests are “revolutionary” applications of 
knowledge from “the book of life,” or instances of unacceptable hubris 
that “play God” and run the “risk” of unleashing “Frankenstein” creations 
(Hellsten 2005).
 The use of metaphors and scientifi cally imprecise language is arguably 
an important means of translating, explaining, and simplifying complex 
ideas and is thus widespread in popular science and media discourses. But 
such language is not unproblematic (López 2004; Petersen, Anderson, and 
Allan 2005). Public representations of genomics research and applications 
often invoke simplistic, reductionist, or deterministic explanations for 
things that are signifi cantly more complex. The mention of “genetics” or 
“genetically tailored drugs” creates expectations that highly effective and 
safe designer medicines will soon be available to the general public (Smart 
2003). Similarly, when the diagnostics industry or academic groups seek-
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ing research funding or venture-capital discuss the implications of their 
fi ndings (e.g., in relation to variability in treatment outcomes), these are 
often attributed to “genetics” and thus tend to dismiss the role of non-
genetic factors (Bowen, Battuello, and Raats 2005; Williams-Jones 2006).
 Despite its frequent use, the term “genetics” is rarely contextualized in 
suffi cient detail. Specifi cally, it is important to understand the different 
meanings of “genetics” in “biological dogma” and in “risk assessment” for 
medical outcomes such as drug response and disease susceptibility. 
 Biological dogma is a term that describes a fundamental process in cell biol-
ogy: the unidirectional fl ow of biological information from the nucleotide 
sequences coded in individuals’ genetic material (DNA), to messenger RNA 
(mRNA), through the process of gene transcription, and fi nally to proteins 
via translation of mRNA by cellular ribosomal machinery. Seen through 
the lens of biological dogma, then, DNA and genes are undoubtedly the 
indispensable currencies of all eukaryotic life forms (including humans), 
and thus a key focus for genomics research. Pharmacogenomics research, 
however, is about “risk assessment” and so poses a conceptually different 
question: Does human genetic variation, either in gene sequence or in the 
regulation of gene expression (transcription), explain person-to-person dif-
ferences in drug effi cacy or toxicity? Hence, while genes are an indispens-
able requirement in the context of the biological dogma, they are only one 
of many factors that contribute to the fi nal composite risk for drug-related 
problems. The interchangeable use of the term genetics in either context — 
biological dogma or pharmacogenomics-based risk assessment — incorrectly 
implies a greater role for hereditary factors in pharmacogenomics.
 Unfortunately, representations of “genetics” in the media or industry 
promotional press releases often erroneously refer to the biological dogma 
itself as the key focus of pharmacogenomics or human genetics research 
(Terwilliger and Weiss 2003). Rhetoric about the role of genes in sustaining 
“life” (i.e., more accurately, the biological dogma) is presented to support 
the importance of genetic factors for drug response. Such genetics talk is 
inherently misleading to non-specialist consumers of genomic technolo-
gies and may ultimately breach the public’s trust in science and genetics 
research (Nelkin 2001). Thus, it is important to ensure that the public, as 
potential consumers of pharmacogenomic tests, and their physicians, as 
prescribers of personalized medicines, are able to adequately distinguish 
different meanings of “genetics” in risk assessment or discussions of the 
biological dogma. 
Promissory Science and Genohype in the Evolution of 
Pharmacogenomics
The use of simplistic and reductionist language in public and policy 
discourse also links in important ways to concerns about the extent to 
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which the promises of genomics and biotechnology will be actualized in 
clinical practice. Can pharmacogenomics deliver personalized medicines 
in a timely manner, or will it go the way of other genomics promises where 
“genohype” did not lead to “genoreality” (Ozdemir et al. 2005; Webster et 
al. 2004)? 
 The substantial historical — and continued — investment in genomics 
research by governments and corporations of developed and developing 
nations has been publicly justifi ed on the grounds that this so-called new 
science would produce the necessary knowledge and derivative biotechnol-
ogies to solve many of the world’s most challenging social, environmental, 
and economic problems. The Human Genome Project, for example, was 
billed as the means for identifying both rare and common disease suscept-
ibility genes (e.g., for obesity, cancer, diabetes), information that could be 
quickly translated into cheap and accurate diagnostics to be followed soon 
after by gene therapies and personalized medicines. Genetics was (is) to 
be the future of medicine (Collins and McKusick 2001; United Kingdom 
Department of Health 2003).
 Yet, while the completion of the Human Genome Project may have 
allowed the “language” of DNA to become “readable”, knowing the 
sequence of coding “letters” (base pairs) and deciphering some of the 
“words” (genes) has proven insuffi cient for a complete comprehension of 
the structure and function of the genome. The publication of the com-
pleted human genome map has thus been followed by other maps (e.g., 
the International HapMap Consortium) — genomics is only the beginning 
of what is likely to be a decades-long research endeavour to understand 
the complex interactions among genes, proteins, environment, socio-eco-
nomic, and cultural factors (Heymann et al. 2005; Terwilliger and Weiss 
2003).
 As numerous science, policy, and social science commentators have 
noted, the promissory fi elds of genomics and biotechnology have yet to 
deliver on most of the predicted “revolutionary” technologies (Ozdemir 
and Godard 2007). There have been important discoveries and develop-
ments, but these have tended to be incremental, following pre-existing 
and well-established lines of research (Nightingale and Martin 2004). For 
example, while a growing number of medical genetic tests have become 
available in the clinic and the marketplace, many of these tests were 
developed after decades of research involving detailed and extended family 
histories of hereditary disease. And for the most part, these tests are useful 
only for identifying or providing risk information about rare hereditary 
diseases; seldom are they suffi ciently accurate for wider population screen-
ing (Baird 2000; British Medical Association 2005). Similarly, while many 
of the technical advances (e.g., DNA microarrays) can be represented as 
“engineering triumphs,” they still require interpretation in the context of 
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biology, clinical biomedicine, and commercial biotechnologies. The trans-
lation of genomics knowledge into scientifi cally and economically import-
ant biotechnologies has proven far more complicated than expected.
 In the case of pharmacogenomics, proponents argue that the genetic 
customization of drugs will both radically improve medical outcomes 
by eliminating ADRs and develop new avenues for commercialization of 
pharmaceuticals and genetic technologies (Roses 2000). As with genetic 
testing, pharmacogenomics is being applied and is proving useful for some 
people (Dervieux, Meshkin, and Neri 2005). But despite high expectations, 
only a small number of pharmacogenomic products have actually entered 
clinical practice, and even these remain contentious (Woelderink et al. 
2006). 
 For Herceptin, one of the fi rst generation of personalized medicines, 
there has been some debate about whether or not this drug is in fact an 
instance of pharmacogenomics (Hedgecoe 2005; Lindpaintner et al. 2001). 
Herceptin is a monoclonal antibody directed at the human epidermal 
growth factor receptor 2 (HER2). It was approved by the US Food and Drug 
Administration in 1998 as an anti-cancer therapy for breast cancer patients 
who are HER2 positive. The Herceptin pharmacogenomic test involves 
the characterization of HER2 expression levels in tumour biopsy materi-
als. A clearly discernible drug target, HER2 was a foreseeable candidate 
for diagnostic testing, the clinical adoption of which was facilitated by 
the relatively easy access to biopsy samples. In other medical specialties, 
such as psychiatry, obtaining target organ tissue samples for measurement 
of gene expression is not possible for obvious practical and ethical rea-
sons. Instead, genetic tests using DNA from peripheral tissues (e.g., blood) 
remains the sole means of pharmacogenomic testing. Another notable 
aspect of the HER2 test is that it was not identifi ed by a genome-wide search 
but rather by virtue of HER2 being a drug target whose expression levels 
may understandably infl uence treatment outcomes. In this light, HER2 
is perhaps more appropriately framed as a product of classical pharmaco-
genetics rather than as an instance of a revolutionary pharmacogenomic 
technology. 
 Abacavir, a drug used to treat HIV-1, is associated with systemic hyper-
sensitivity reactions in about 5 percent of patients. Genetic screening of 
these persons for the human major histocompatibility complex identifi ed 
several susceptibility loci (Symonds et al. 2002). One particular allele, 
HLA-B*5701, was overrepresented among the Abacavir-hypersensitive 
patients in studies reported from Western Australia and North America 
and thus could be used as a pharmacogenomic test to identify at-risk per-
sons who should not receive the drug (for an overview, see Quirk, McLeod, 
and Powderly 2004). Some would argue, however, that the Abacavir story 
is hyped and that the utility of pharmacogenomic testing is at best limited 
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(Lindpaintner 2002). The HLA-B*5701 allele does not account for all adverse 
reactions to Abacavir because people who do not carry this allele can also 
have a hypersensitivity reaction. Moreover, because exposure to Abacavir 
can lead to serious medical complications in hypersensitive patients, it is 
critical that the full complement of genetic and environmental risk fac-
tors be identifi ed before pharmacogenomic testing can effectively guide 
prescription decisions.
 Gleevec, a drug to treat persons with chronic myeloid leukemia who 
test positive for the Philadelphia chromosome (an abnormally short 
chromosome 22 identifi ed in 1960), is likely a more clear-cut case of a 
functioning pharmacogenomic test and drug application. But this drug-
test combination is based on a relatively simple cytogenetic test and would 
probably have been feasible without genomic technologies. An important 
point to note, then, is that the discovery of these drugs did not emerge 
from “genome-wide” searches per se, one of the long advocated key deliv-
erables of pharmacogenomics research. The attendant diagnostic tests were 
developed through more focused candidate gene studies (i.e., pharmaco-
genetics) or simply by using classical cytogenetic approaches. Further, the 
development of diagnostic tests for drug response appears to be an ad hoc 
effort rather than a prospective systematic approach in response to a ser-
ious adverse drug event or lack of effi cacy.
 An important goal of pharmacogenomics has been the identifi cation of 
genes or biomarkers that are diffi cult to forecast from existing knowledge 
of a drug’s chemistry or the disease pathophysiology. As with research into 
gene therapy, the enormous complexity of pharmacogenomics research 
and technology development means that much work remains before scien-
tifi c discoveries will be readily translated into clinical applications (Freund 
and Wilfond 2002).
 Investors, governments, and some in the pharmaceutical industry have 
also placed much hope on pharmacogenomics as the vehicle for re-ener-
gizing and reshaping the struggling pharmaceutical sector. Pharmaceutical 
companies have in the last ten years been fi nding it increasingly diffi cult 
to develop and market new blockbuster drugs — most new medications are 
“me too” drugs (Center for Drug Evaluation and Research 2005; Horrobin 
2000). Further, a large number of blockbuster composition of matter 
patents are due to expire over the next several years, further threatening 
big pharma’s economic model (Service 2004). In this context, upstream 
pharmacogenomic applications promise to help academic and industry 
researchers identify new disease-associated genes, some of which may 
serve as novel drug targets. Developments in pharmacogenomics may also 
enable companies to risk-proof their drug development pipelines by pre-
venting catastrophic and extremely costly late-stage drug withdrawals (or 
class action lawsuits) because of unacceptable toxicity or lack of effi cacy. 
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Pharmacogenomics may even revive, in specifi c subpopulations, patented 
and developed but uncommercialized drugs that failed during the clinical 
trial stage because of safety concerns or lack of effi cacy in the broader 
patient population (Ozdemir and Lerer 2005).
 The economic potential of pharmacogenomics, and the corresponding 
benefi t for the pharmaceutical industry, may not however be so straight-
forward. The process of identifying genetic markers in individuals and 
communities creates pharmacological and disease subtypes that inevitably 
fragment both the disease and its treatment. That is, by personalizing medi-
cines, pharmacogenomics undermines the traditional blockbuster model 
of drug development and marketing. No longer is it suffi cient to develop a 
one-size-fi ts-all medication that will hopefully generate billions of dollars 
in revenues (i.e., be a blockbuster) (Danzon and Towse 2002); instead, a 
variety of personalized medications will be necessary for each molecular 
genetic subtype of disease or individual drug response. The upshot is a 
fragmented market and increased competition (or more complex collab-
orations) between drug manufacturers and biotechnology companies. 
Not surprisingly, then, individual pharmaceutical companies may have 
divergent views within their own constituents (e.g., among directors of 
marketing, genetics, or chemistry departments) about the appropriateness 
of pursing pharmacogenomics, at least in the short term (Williams-Jones 
and Corrigan 2003). It is very likely, however, that pharmacogenomics 
will make future predictions on drug effi cacy and safety more reliable 
and reduce the risk for catastrophic and costly late-stage drug withdrawals 
from the market; but when and to whom these benefi ts will accrue is much 
harder to discern (Eisenberg 2002).
 Such profound disconnects between the promises and realities of 
genomic knowledge and technologies have led many commentators to 
question the motivations of genomics advocates (whether they be academ-
ics, pharmaceutical or biotechnology industry representatives, or venture 
capital fi rms), and the veracity of their claims, and even to label these 
promises as “genohype” (Fleising 2001). 
 Hype may well be an important, even essential, part of the develop-
mental phase of a new science or technology. Positive spin can facilitate 
collaboration and uptake of new ideas; help in the acquisition of human, 
fi nancial, and technical resources; and create a future-oriented conscious-
ness about how the “new” will be an improvement over the “old” (Brown 
2003; Hedgecoe and Martin 2003). However, while hype can be an effective 
means of achieving near-term objectives, it can also be counterproductive 
in the long run when not matched by tangible products.
 Unfi lled promises can severely undermine the credibility of stakehold-
ers, be they scientists, technologists, companies, or governments. For 
example, when surrounded by academic, commercial, or other supporters 
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of the promissory science, and in the face of hype and unrealistic public 
expectations, scientists genuinely committed to the attendant fi eld of 
enquiry may become discouraged, feel pressured to pursue short-term goals 
centred on immediacy, or even decide to shift their research entirely to less 
hyped areas of scientifi c enquiry. By focusing on the short- to medium-
term potentials of particular fi elds of enquiry or early-stage technologies, 
hype may also obscure the long-term potential of a new fi eld of innovation 
(Caulfi eld 2000). 
 A more subtle and yet signifi cant consequence of genohype is that it 
diverts attention from how the benefi ts of pharmacogenomics are to be 
distributed among the world’s populations and the ways in which pharma-
cogenomic testing may shape healthcare delivery and treatment of diseases 
predominantly affecting developing countries.
Pharmacogenomics in the Developing World and the “90/10 Gap”
As discussed above, pharmacogenomics has traditionally been framed in 
the context of individualization of patented fi rst-line drugs for illnesses 
such as type 2 diabetes or cancer, diseases that primarily affect the popula-
tions of developed and affl uent countries. It is not surprising, then, that 
some would question the relevance of pharmacogenomics to the discovery 
and cost-effective delivery of drugs that will actually benefi t patients in 
the developing world (Pang 2003).
 Private and public investment in health research is estimated to be more 
than US$70 billion per year (Vijayanathan, Thomas, and Thomas 2002). 
However, less than 10 percent of global funding for research is directed 
toward diseases that affect more than 90 percent of the world’s popula-
tion — the so-called “90/10 gap” (Institute for OneWorld Health 2004). 
This situation is made worse by often inadequate research infrastructure 
and lack of trained personnel in developing countries who can conduct 
or advocate for research to tackle prevalent diseases such as malaria or 
tuberculosis. Because of wide disparities in wealth distribution and lack of 
a middle socio-economic class in resource-poor nations, efforts to develop 
local research capacity by training personnel abroad may also prove chal-
lenging. In particular, there may be uncertainty about who should have 
the opportunity to pursue academic training abroad (e.g., based on scien-
tifi c and individual merit or socio-economic privilege?), not to mention 
diffi culties in ensuring professional commitment and encouraging highly 
skilled scientists to return to their native countries (Hyder, Akhter, and 
Qayyum 2003).
 In 1977, the World Health Organization (WHO) launched the Model 
List of Essential Medicines to identify and facilitate the provision of safe 
and effective treatments for communicable and chronic diseases affect-
ing the vast majority of the world’s population. This list is updated every 
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two years by an expert committee to include drugs that will satisfy the 
priority healthcare needs of the population. The selection criterion takes 
into account public health relevance, evidence on effi cacy and safety, and 
cost-effectiveness (Day et al. 2005). The concept of essential drugs is also 
a valuable measure to reduce irrational drug combinations or counterfeit 
products; the WHO donor programs use only the drugs listed in the model 
list. 
 Yet, of the 1,393 new drugs developed between 1975 and 1999, only 1.1 
percent (16 drugs) were for the treatment or prevention of tropical and 
other diseases prevalent in developing countries (Trouiller et al. 2002). 
The commercial logic of contemporary drug development and marketing 
is such that developing countries are simply not a good market for fi rst-
line pharmaceuticals, nor are their diseases worth the research investment. 
Unlike drugs for chronic diseases that require multiple prescription refi lls 
(e.g., statins to lower cholesterol levels and reduce cardiovascular risk), and 
thus for which there is a substantial market in the West, antiviral drugs are 
not a profi table investment unless they also affect affl uent countries (e.g., 
drug cocktails for “chronic” HIV infection or vaccines for avian infl uenza) 
because they are prescribed for a limited period. 
 A second critical element is ability to pay. Developing countries lack 
the large-scale public and private health-insurance programs common 
in North America and Europe that would cover the costs of prescription 
medications, nor do the peoples of developing countries have the personal 
wealth to afford costly drugs — one-third of the world’s population lives on 
less than US$2 a day. Thus, while sub-Saharan Africa, for example, could 
provide a very large “volume” of clients for antiviral drugs or vaccines, 
they are too poor to pay even a reduced bulk price that might be offered 
by the big pharmas. Multinational regulation of trade and intellectual 
property rights, in particular the Agreement on Trade-Related Aspects of 
Intellectual Property Rights (TRIPS Agreement), may further hinder access 
to patented drugs in developing countries. Although the TRIPS Agreement, 
in the event of a public health emergency, allows for compulsory licens-
ing by local governments, it is unclear whether this provides any help for 
countries with limited manufacturing infrastructure.
 The high relative cost of pharmaceuticals in developing countries has 
a profound economic and social impact (Hale, Woo, and Lipton 2005). 
According to the WHO, “while spending on pharmaceuticals represents 
less than one-fi fth of total public and private health spending in most 
developed countries, it represents 15 to 30 percent of health spending in 
transitional economies and 25 percent to 66 percent in developing coun-
tries. In most low-income countries pharmaceuticals are the largest public 
expenditure on health after personnel costs and the largest household 
health expenditure. And the expense of serious family illness, including 
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drugs, is a major cause of household impoverishment” (WHO Medicines 
Policy and Standards 2007).
 The result is global injustice and a widening gap in access to essential 
medicines between developed and resource-poor nations. Through no 
fault of their own — one’s birthplace is obviously outside one’s control — 
those people least able to afford basic (but costly) drugs live in poverty 
and in countries unable to provide affordable healthcare services. These 
people spend the largest percentage of their incomes acquiring essential 
medicines, whereas the majority of their wealthy neighbours in the North 
have access to a surplus of me-too drugs, a diversity of relatively afford-
able generic medicines, and a health insurance system to cover much of 
the costs. Given these profound social inequities, of what relevance is a 
developing but still not fully actualized and thus very expensive technol-
ogy such as pharmacogenomics?
 Given the upfront costs of genomics research and the development of 
pharmacogenomics technologies, in all likelihood drugs developed by 
pharmacogenomic guidance will be prohibitively costly for equitable 
access in developing countries. It is reasonable, then, to argue that other 
tested public health measures, such as the provision of clean water and 
equitable access to housing, would be a better use of the limited fi nancial 
resources available for international development (Heymann et al. 2005). 
Thus, although genomics research or applied biotechnologies may benefi t 
wealthier populations or individuals, it is not at all clear to many com-
mentators how these technologies will address the serious issues of global 
public health and distributive justice (Dwyer 2005).
 Despite these important critiques of pharmacogenomics (and other bio-
technologies), there are two areas in which pharmacogenomics research 
might help with the equitable and timely provision of appropriate medi-
cines in developing countries. The application of pharmacogenomics 
might (1) enable the provision of inexpensive generic drugs in subpopula-
tions defi ned by pharmacogenomic tests wherein drugs display an opti-
mal benefi t-to-risk ratio, and (2) facilitate investment in the discovery of 
medicines for diseases such as malaria or parasitic infections.
 It is conceivable, particularly given growing concerns about equitable 
access to safe and effective medications, that an internationally accepted 
and peer-reviewed essential biomarkers directory similar to the essential 
medicines library maintained by the WHO could be established. Such a 
biomarker directory would enable a broader utility for pharmacogenomic 
biomarkers by permitting the reintroduction of less costly second-line gen-
eric drugs with suboptimal safety as fi rst-line treatments in subpopulations 
that demonstrate an improved benefi t-risk ratio (Ozdemir et al. 2006). This 
possibility (i.e., a means of marketing patented but uncommercialized 
drugs) is also one of the hopes of pharmacogenomic advocates in the phar-
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maceutical industry, but for it to be applicable in the context of developing 
countries, it would have to be applied in concert with a different mar-
ket model of drug provision. Specifi cally, drug developers would need to 
accept that the opportunity to market patented but shelved drugs brings 
with it a corollary obligation to market those drugs at a price affordable to 
developing countries. The payoff for drug companies would be profi ts from 
the sale (of relatively) large volumes of a medication that would otherwise 
be generating no revenues, as well as a means of enhancing their rather 
tarnished public images by seriously addressing the critical public health 
concerns of people in developing countries.
 As part of their corporate social-responsibility programs, many big phar-
mas already donate drugs to developing countries; for example, Merck 
donates the drug ivermectin (Stromectol) for the treatment of river blind-
ness in western and central Africa. However, these donations have had a 
limited effect on the provision of treatments for the broad range of diseases 
affecting developing countries. Another and more innovative approach is 
the development of public-private partnerships, wherein drug companies 
partner with not-for-profi t foundations to engage in drug development for 
marginalized or orphan disease areas. A notable example is the Institute 
for OneWorld Health, a non-profi t drug-development company that is 
partnering with big pharmas, small biotechs, and large public trusts such 
as the Bill and Melinda Gates Foundation to conduct clinical trials and 
develop a range of drugs for diseases affecting peoples in developing coun-
tries. For example, with a broad licence donation of a molecule owned by 
Celera Genomics, OneWorld Health is developing a treatment for Chagas’ 
disease (Hale, Woo, and Lipton 2005). 
 Such a merging of innovative business strategies with developments in 
biotechnology and pharmacogenomics research may allow for more cost-
effective identifi cation of novel drug targets and pharmacological mechan-
isms for neglected diseases, and, it is hoped, lead to increased local access to 
affordable and effective drugs (Daar and Singer 2005). But although pharma-
cogenomic technologies may be valuable tools for improving global public 
health (in the long run), there are serious concerns over their representation 
as tools that will necessarily benefi t science and the public interest in the 
near term. In comparison with other well-known social, cultural, or eco-
nomic responses to the profound healthcare challenges facing developing 
nations or transitional economies, the potential and cost-effectiveness 
of pharmacogenomic technologies remains a contentious issue. Whether 
these technologies are applied as part of the standard big pharma business 
model or integrated in public-private partnerships around non-profi t drug 
development, ultimately the question remains, who is going to fund the 
long-term research to actualize the potential of pharmacogenomics and 
translate knowledge into action (Pang, Gray, and Evans 2006)?
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Conclusion: An Equitable Integration of Pharmacogenomics 
in Healthcare?
For pharmacogenomics “genohype” to become “genoreality,” basic scien-
tifi c and clinical discoveries associated with the genetics of drug effect and 
response must be converted into technologies that actually make a differ-
ence in the real world. Short of such translation of knowledge into product, 
the public as citizens and taxpayers may come to feel they have again been 
sold a bill of goods, so to speak. A related point is that pharmacogenomics, 
so far, has been largely an engineering triumph — the vast amount of infor-
mation generated by genomics research is being transformed into phar-
macogenomic tests that are helping researchers build more sophisticated 
understandings of individual and population variability in drug response. 
But translational biomarker research that transforms knowledge into 
functional pharmacogenomic tests and linked drugs will be crucial if this 
fi eld is to also achieve a biological triumph. Only when the engineering 
triumph is matched with a biological triumph will the genohype become a 
genoreality. It is tempting to say, then, that part of the cause of genohype 
is the mismatch between these two very different types of triumph.
 Developed and more affl uent countries have a vested self-interest in 
advocating for global justice in access to essential medicines and provision 
of healthcare services in resource-poor countries. Recent world events such 
as the SARS outbreak in 2003, the AIDS pandemic, and the threat of avian 
infl uenza have shown the close relationships among national interests, 
global public health emergencies (regardless of geographical localization), 
and access to equitable healthcare services, including pharmacotherapy. 
 While refl ecting on the promises of pharmacogenomics, it thus seems 
appropriate to pay attention to the ways in which new genomic technolo-
gies can benefi t developing countries, for example, by the discovery of 
new drug targets for infectious diseases or treatment of resistance forms 
of tuberculosis. However, inadequate recognition of the strengths and 
limitations of pharmacogenomic technologies can widen the already 
existing gap in pharmaceutical research and access to equitable pharma-
cotherapies. In particular, the “90/10 gap” may become more pronounced 
unless the emerging pharmacogenomic technologies are appropriately 
evaluated regarding their implementation in populations with divergent 
socio-economic predicaments. 
 Finally, given the continued lack of access to essential medicines in 
developing countries, profound questions remain about how best to 
deploy limited fi nancial resources, whether it be for the individualization 
of drug therapy or for other measures known to markedly improve health 
and prevent disease, such as access to clean water, education on sexually 
transmitted diseases (e.g., AIDS), adequate housing, and employment. 
Ultimately, however, it will still be important to evaluate both the social 
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(environmental, economic, and cultural) and biological (genetic) factors, 
as well as their complex interactions, in order that biotechnologies and 
pharmacotherapies can collectively aid in the improvement of global pub-
lic health (Heymann et al. 2005).
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